drugset / Trial / NCT01310738
Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil
Phase 4
Terminated
378 enrolled
University of Brasilia
Conselho Nacional de Desenvolvimento Científico e Tecnológico · collabDrugs for Neglected Diseases · collabMinistry of Health, Brazil · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is aimed to compare the efficacy and safety of medications currently used in Brazil for treatment of visceral leishmaniasis. The investigators will compare the effects of meglumine antimoniate, two formulations of amphotericin B: deoxycholate and liposomal, and a combination of meglumine plus the liposomal amphotericin B formulation. The study is designed to demonstrate the difference in efficacy measured as cure rate at six months after treatment and the safety profile based on the adverse event rate observed with each intervention.
Timeline
- Start
- 2011-02
- Primary completion
- 2014-10
- Completion
- 2015-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amphotericin B | Unknown | 3 mg/kg | Intravenous |
| Subject | Amphotericin B | Unknown | 10 mg/kg | Intravenous |
| Subject | Meglumine antimonate | Other / unclassified | 20 mg/kg | Intravenous |
| Subject | amphotericin B deoxycholate | Unknown | 1 mg/kg | Intravenous |